Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a research report report published on Tuesday. Separately, Truist Financial cut their price target on Compugen from $5.00 to $4.00 and set a buy rating for the company in a research note on Tuesday. View Our Latest […]
Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's First Quarter 2024 Results Conference Call. At this time, all participants are in a listen-only mode.
Has released an update. Compugen Ltd., a clinical-stage immunotherapy company, has provided updates for Q1 2024, announcing complet...
Compugen Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 2.56 million. Net loss was USD 7.27 million compared to...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...